Astatine-211 Meta-Astatobenzylguanidine ([211At]MABG) Targeted Radiotherapy for Disseminated Neuroblastoma |
Children’s Hospital of Philadelphia / John Maris, MD |
Reach Grants |
2016 |
Pennsylvania |
IND-Enabling Studies for WNTinib, a Novel Selective Therapeutic for CTNNB1 Mutant Hepatoblastomas |
Icahn School of Medicine at Mount Sinai / Ernesto Guccione, PhD & Josep Llovet, MD & Arvin Dar, PhD |
Reach Grants |
2021 |
New York |
Targeting PLK1 as a Common Mechanism in Ph-like ALL |
University of Texas M.D. Anderson Cancer Center / Joya Chandra, PhD |
Reach Grants |
2016 |
Texas |
Circumventing Pediatric Solid Tumor Microenvironment Resistance by Combinatorial CAR NK and Immunomodulating Therapy |
New York Medical College / Mitchell Cairo, MD |
Reach Grants |
2023 |
New York |
Feasibility Study of Dual Inhibition of MDM2 and Tubulin in Treatment of AML |
Emory University / Muxiang Zhou, MD |
Reach Grants |
2023 |
Georgia |
Targeting RNA Helicase DDX3 to Treat Recurrent High Grade Sarcoma
|
The Johns Hopkins University School of Medicine / David Loeb, MD, PhD |
Reach Grants |
2013 |
Maryland |
Preclinical Development of Targeted Therapy for Neuroblastoma with ALK and CDK4/6 Dual Pathway Inhibition
|
Children’s Hospital of Philadelphia / Yael Mossé, MD |
Reach Grants |
2013 |
Pennsylvania |
Therapeutic Reactivation of p53 to Overcome Apoptotic Resistance in Pediatric Leukemia |
Dana-Farber Cancer Institute / Loren Walensky, MD, PhD & Kimberly Stegmaier, MD |
Reach Grants |
2015 |
Massachusetts |
Epigenomics of High Risk Pediatric T Cell Leukemia |
New York University School of Medicine / Iannis Aifantis, PhD |
Reach Grants |
2013 |
New York |
Development of a Pharmacodynamic Marker of EWS-FLI1 Activity to Aid in the Clinical Translation of Targeted Therapies for Ewing sarcoma |
Van Andel Research Institute / Patrick Grohar, MD, PhD |
Reach Grants |
2013 |
Michigan |